KERBY MCDONALD: Open Payments
NPI 1053662007 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,768 in 120 payments from 21 companies in 2025. Trend: 2023 $1,995 · 2024 $1,620 · 2025 $2,768
Food & beverage: $2,768
| Company | Payments | Amount |
|---|---|---|
| ARGENX US, INC. | 12 | $343 |
| Eisai Inc. | 12 | $310 |
| ABBVIE INC. | 12 | $281 |
| UCB, Inc. | 15 | $239 |
| Teva Pharmaceuticals USA, Inc. | 9 | $237 |
| Neurelis, Inc. | 9 | $213 |
| Lilly USA, LLC | 8 | $161 |
| Alexion Pharmaceuticals, Inc. | 5 | $153 |
| ACADIA Pharmaceuticals Inc | 6 | $147 |
| Novartis Pharmaceuticals Corporation | 7 | $126 |
Products named: VYVGART HYTRULO, Leqembi, AUSTEDO XR, VALTOCO, ULTOMIRIS, KISUNLA, NUPLAZID, VRAYLAR.
Industry payments across AZ — which companies pay providers there.
